Speciality: Oncology
Description:
Welcome to this insightful expert discussion on the treatment paradigm for patients with relapsed/refractory (R/R) adult B-cell acute lymphoblastic leukemia (ALL). Renowned hematologists and oncologists, Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja, share their valuable perspectives on the latest advancements, challenges, and emerging therapies in managing this aggressive condition. The panel delves into key topics such as novel immunotherapies, targeted treatments, and personalized approaches that are reshaping outcomes for R/R B-cell ALL patients.
The experts critically evaluate current treatment strategies, including CAR T-cell therapy, bispecific antibodies, and small-molecule inhibitors, while discussing real-world clinical experiences and patient selection criteria. They also highlight the importance of multidisciplinary care and the need for early intervention to improve survival rates. Their in-depth analysis provides clinicians with practical insights to navigate complex treatment decisions in this rapidly evolving field.
Don’t miss this engaging and informative session that bridges cutting-edge research with clinical practice. Stay tuned for more expert-led discussions that aim to enhance knowledge and improve patient care in hematologic malignancies. Watch the full video to gain comprehensive insights from these distinguished thought leaders!
See More Webinars @ Hidoc Webinars
1.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
2.
a brand-new generic therapy for different types of cancer.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
5.
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types
1.
Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology
2.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
3.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
4.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation